Sanofi $SNY Shares Purchased by Cibc World Market Inc.

Cibc World Market Inc. grew its position in Sanofi (NASDAQ:SNY) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 374,816 shares of the company’s stock after buying an additional 14,325 shares during the period. Cibc World Market Inc.’s holdings in Sanofi were worth $17,691,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. raised its position in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the period. Franklin Resources Inc. raised its stake in shares of Sanofi by 9.9% in the 2nd quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after acquiring an additional 384,902 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Sanofi by 4.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,434,999 shares of the company’s stock worth $165,945,000 after acquiring an additional 157,605 shares during the last quarter. Equity Investment Corp boosted its position in shares of Sanofi by 3.0% during the 3rd quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock worth $122,139,000 after purchasing an additional 75,255 shares during the period. Finally, Brandes Investment Partners LP increased its holdings in Sanofi by 9.1% in the 2nd quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock valued at $119,992,000 after purchasing an additional 208,090 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi completed its acquisition of Dynavax, strengthening its adult vaccine portfolio (adds CpG-adjuvant technology and vaccine candidates that could boost medium‑term commercial and pipeline prospects). Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi’s board named Belén Garijo as CEO in a formal appointment/press release — markets will be watching her near-term communications, strategy priorities and any shifts in R&D or capital allocation. Who is Sanofi’s new CEO Belén Garijo?
• Neutral Sentiment: Trading activity is elevated (roughly 10.8M shares vs ~4.2M average), indicating heavy repositioning; elevated volume can amplify volatility while investors digest corporate governance and strategy signals. Sanofi downgrade note
• Negative Sentiment: The board’s decision not to renew Paul Hudson’s mandate was widely reported as an abrupt ouster, creating headline-driven uncertainty about leadership stability and execution risk — selling pressure followed those reports. Sanofi tumbles after board shockingly ousts CEO Paul Hudson
• Negative Sentiment: Bank of America downgraded Sanofi from Buy to Neutral, which can reduce buy-side conviction and remove a source of upward price support in the near term. Sanofi downgraded by Bank of America

Analysts Set New Price Targets

SNY has been the topic of several research reports. Wall Street Zen raised Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Sanofi currently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Price Performance

SNY stock opened at $47.03 on Friday. The business has a 50 day moving average price of $47.80 and a 200 day moving average price of $48.62. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a market cap of $114.71 billion, a price-to-earnings ratio of 13.06, a PEG ratio of 1.28 and a beta of 0.45. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.